Dynavax Technologies saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 71.
IBD's unique rating tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating of above 80 as they launch their biggest runs. See if Dynavax Technologies can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Dynavax Technologies is trying to complete a cup with handle with a 13.89 entry. See if the stock can break out in heavy volume.
The company showed 20% earnings growth in its most recent report, while sales growth came in at 16%.
The company holds the No. 35 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
